Results 121 to 130 of about 35,846 (211)

GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review. [PDF]

Adv Ther
Pantazopoulos D, Gouveri E, Papi M, Papazoglou D, Papanas N.   +4 more
europepmc   +1 more source

Mechanisms of beneficial effects of DPP-4 inhibitors as a promising perspective for the prevention/treatment of the disruption of cardio-cerebrovascular homeostasis. [PDF]

Front Pharmacol
Pavlović KT, Anderluh M, Šmelcerović A.   +2 more
europepmc   +1 more source

Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis. [PDF]

Diabetol Metab Syndr
Hajishah H, Mazloom P, Salehi A, Kazemi D, Samiee R, Majlesi H, Amini MJ, Meyari A, Dehnavi NS, Zangi M.   +9 more
europepmc   +1 more source

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [PDF]

, 2016
Daisuke Koya, Keizo Kanasaki, Sen Shi
core   +1 more source

Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]

Cureus
Prakash V, Goel N.
europepmc   +1 more source

Treatment preference for once-weekly versus once-daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med
Xie X, Chen Y, Wang P, Hu M.
europepmc   +1 more source

Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study. [PDF]

ERJ Open Res
Yen FS, Wei JC, Ko FS, Huang Y, Yip HT, Tsai FJ, Hwu CM, Hsu CC.   +7 more
europepmc   +1 more source

Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis. [PDF]

Ann Med Surg (Lond)
Amini-Salehi E, Hasanpour M, Alotaibi A, Rashidian P, Hashemi SM, Nasrollahizadeh A, Letafatkar N, Saberian P, Amani-Beni R, Shanbehzadeh N.   +9 more
europepmc   +1 more source

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease? [PDF]

, 2015

core   +1 more source

Imeglimin and DPP-4 inhibitors: A promising therapeutic strategy for type 2 diabetes individuals with reduced insulin secretion. [PDF]

Diabetes Obes Metab
Hamamoto Y, Usui R.
europepmc   +1 more source